A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT01017952
Last Updated: 2018-08-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1635 participants
INTERVENTIONAL
2009-09-25
2011-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01009463
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01054885
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01053988
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
NCT01192191
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FF/GW642444 Inhalation Powder 100/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
FF/GW642444 Inhalation Powder 50mcg/25mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
FF/GW642444 Inhalation Powder 200/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
GW642444 25mcg QD
Long Acting Beta Agonist(LABA)
GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent: Subjects must give their signed and dated written informed consent to participate.
* Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH \> 40MIU/ml and estradiol \<40pg/ml (\<140 pmol/L) is confirmatory. OR
Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):
* Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
* Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
* Implants of levonorgestral inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
* Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
* Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
* Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
* An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
* Estrogenic vaginal ring; or
* Percutaneous contraceptive patches
* Age: ≥40 years of age at Screening (Visit 1)
* COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society \[Celli, 2004\]: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
* Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. Number of pack years = (number of cigarettes per day/20) x number of years smoked
* Severity of Disease:
* Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)
* Subjects with a measured post-albuterol/salbutamol FEV1 \<70% of predicted normal values calculated (via centralized vendor equipment) using NHANES III reference equations \[Hankinson, 1999\] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber. The study provided central spirometry equipment will calculate the FEV1/FVC ratio and FEV1 percent predicted values.
* History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable.
Exclusion Criteria
* Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
* Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
* α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
* Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
* Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
* Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit 1), the subject will not be eligible for the study.
* Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's, Myasthenia Gravis, etc).
* A moderate and severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
* Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue in the study, but may be re-screened at a later time provided the pneumonia and/or COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit must be conducted at least ≥ 14 days following the resolution date of the exacerbation and/or pneumonia and at least 30 days following the last dose of oral corticosteroids (if applicable).
* Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
* Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.
* Hypertension: Subjects with clinically significant hypertension that is uncontrolled.
* Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
* Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
* Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
* Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to spirometry testing at each study visit.
* Additional medication: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
* Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.
* Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
* Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
* Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
* Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
* Prior use of study medication/other investigational drugs: Subjects who have previously been randomized to treatment with GW642444 Inhalation Powder in the B2C111045 study, randomized to treatment in the HZC111348 study or have participated in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer.
* Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Ozark, Alabama, United States
GSK Investigational Site
Tallassee, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Monterey Park, California, United States
GSK Investigational Site
National City, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Van Nuys, California, United States
GSK Investigational Site
Boulder, Colorado, United States
GSK Investigational Site
Thornton, Colorado, United States
GSK Investigational Site
Hartford, Connecticut, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Cocoa, Florida, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Kissimmee, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Pensacola, Florida, United States
GSK Investigational Site
St. Petersburg, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Gainesville, Georgia, United States
GSK Investigational Site
Martinez, Georgia, United States
GSK Investigational Site
Riverdale, Georgia, United States
GSK Investigational Site
Coeur d'Alene, Idaho, United States
GSK Investigational Site
Aurora, Illinois, United States
GSK Investigational Site
Elk Grove Village, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Council Bluffs, Iowa, United States
GSK Investigational Site
Olathe, Kansas, United States
GSK Investigational Site
Topeka, Kansas, United States
GSK Investigational Site
Hazard, Kentucky, United States
GSK Investigational Site
Madisonville, Kentucky, United States
GSK Investigational Site
Brockton, Massachusetts, United States
GSK Investigational Site
Fall River, Massachusetts, United States
GSK Investigational Site
Pittsfield, Massachusetts, United States
GSK Investigational Site
Cadillac, Michigan, United States
GSK Investigational Site
Edina, Minnesota, United States
GSK Investigational Site
Fridley, Minnesota, United States
GSK Investigational Site
Columbia, Missouri, United States
GSK Investigational Site
Springfield, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Lincoln, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Papillion, Nebraska, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Cherry Hill, New Jersey, United States
GSK Investigational Site
Summit, New Jersey, United States
GSK Investigational Site
Albany, New York, United States
GSK Investigational Site
North Syracuse, New York, United States
GSK Investigational Site
Asheville, North Carolina, United States
GSK Investigational Site
Burlington, North Carolina, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Statesville, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Centerville, Ohio, United States
GSK Investigational Site
Toledo, Ohio, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Columbia, South Carolina, United States
GSK Investigational Site
Easley, South Carolina, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Murrells Inlet, South Carolina, United States
GSK Investigational Site
Pelzer, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
Corsicana, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
New Braunfels, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Wichita Falls, Texas, United States
GSK Investigational Site
Newport News, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Madison, Wisconsin, United States
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
Kingswood, New South Wales, Australia
GSK Investigational Site
Westmead, New South Wales, Australia
GSK Investigational Site
Auchenflower, Queensland, Australia
GSK Investigational Site
Southport, Queensland, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Hobart, Tasmania, Australia
GSK Investigational Site
Box Hill, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Grimsby, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Newmarket, Ontario, Canada
GSK Investigational Site
Sarnia, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Gatineau, Quebec, Canada
GSK Investigational Site
Mirabel, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Puente Alto - Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Talcahuano, , Chile
GSK Investigational Site
Aalborg, , Denmark
GSK Investigational Site
Aarhus C, , Denmark
GSK Investigational Site
Hvidovre, , Denmark
GSK Investigational Site
København NV, , Denmark
GSK Investigational Site
Odense C, , Denmark
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Kassel, Hesse, Germany
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Wiesbaden, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Foggia, Apulia, Italy
GSK Investigational Site
Salerno, Campania, Italy
GSK Investigational Site
San Felice A Cancello Caserta, Campania, Italy
GSK Investigational Site
Modena, Emilia-Romagna, Italy
GSK Investigational Site
Parma, Emilia-Romagna, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Palermo, Sicily, Italy
GSK Investigational Site
Pisa, Tuscany, Italy
GSK Investigational Site
Perugia, Umbria, Italy
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Zapopan, Jalisco, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Almelo, , Netherlands
GSK Investigational Site
Almere Stad, , Netherlands
GSK Investigational Site
Beek, , Netherlands
GSK Investigational Site
Breda, , Netherlands
GSK Investigational Site
Eindhoven, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Hoorn, , Netherlands
GSK Investigational Site
Horn, , Netherlands
GSK Investigational Site
Nieuwegein, , Netherlands
GSK Investigational Site
Zutphen, , Netherlands
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
San Miguel, Lima region, Peru
GSK Investigational Site
Santiago de Surco, Lima region, Peru
GSK Investigational Site
Callao, , Peru
GSK Investigational Site
Meyerspark, Gauteng, South Africa
GSK Investigational Site
Parktown, Gauteng, South Africa
GSK Investigational Site
Waterkloof Ridge, Gauteng, South Africa
GSK Investigational Site
Bellville, , South Africa
GSK Investigational Site
Bloemfontein, , South Africa
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Gatesville, , South Africa
GSK Investigational Site
Mowbray, , South Africa
GSK Investigational Site
Roodepoort, , South Africa
GSK Investigational Site
Worcester, , South Africa
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Cartagena (Murcia), , Spain
GSK Investigational Site
Cáceres, , Spain
GSK Investigational Site
Elda, , Spain
GSK Investigational Site
Galdakano, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Orihuela/Alicante, , Spain
GSK Investigational Site
Pama de Mallorca, , Spain
GSK Investigational Site
Pozuelo de Alarcón/Madrid, , Spain
GSK Investigational Site
Åtvidaberg, , Sweden
GSK Investigational Site
Bankeryd, , Sweden
GSK Investigational Site
Karlskrona, , Sweden
GSK Investigational Site
Lidingö, , Sweden
GSK Investigational Site
Southampton, Hampshire, United Kingdom
GSK Investigational Site
Bradford-on-Avon, Wiltshire, United Kingdom
GSK Investigational Site
Trowbridge, Wiltshire, United Kingdom
GSK Investigational Site
Cambridge, , United Kingdom
GSK Investigational Site
Chertsey, Surrey, , United Kingdom
GSK Investigational Site
Wythenshawe, Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12.
Largajolli A, Beerahee M, Yang S. Bayesian approach to investigate a two-state mixed model of COPD exacerbations. J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):371-384. doi: 10.1007/s10928-019-09643-6. Epub 2019 Jun 13.
Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016 Jun 1;6(6):e010099. doi: 10.1136/bmjopen-2015-010099.
Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.
Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
102970
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.